Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Accumulated Expenses data on file, last reported at $31.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 1.0% year-over-year to $31.5 million; the trailing twelve-month figure through Mar 2026 stood at $31.5 million (up 1.0% YoY), and the FY2025 full-year result was $46.5 million, up 13.96% from the prior year.
• Accumulated Expenses declined to $31.5 million in Q1 2026, from $46.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $46.5 million in Q4 2025 to a low of $21.4 million in Q2 2022.
• A 5-year average of $28.7 million and a median of $28.1 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses declined 16.32% in 2022 and soared 45.14% in 2024, its largest moves.
• Tracing LYEL's Accumulated Expenses over 5 years: stood at $28.8 million in 2022, then decreased by 2.19% to $28.1 million in 2023, then surged by 45.14% to $40.8 million in 2024, then climbed by 13.96% to $46.5 million in 2025, then plunged by 32.33% to $31.5 million in 2026.
• Business Quant data shows LYEL's Accumulated Expenses at $31.5 million in Q1 2026, $46.5 million in Q4 2025, and $29.3 million in Q3 2025.